Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 5.1 EX-5.1
- 8.1 EX-8.1
- 8.2 EX-8.2
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.25 EX-10.25
- 10.26 EX-10.26
- 10.27 EX-10.27
- 10.28 EX-10.28
- 10.31 EX-10.31
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.1 EX-99.1
- 99.3 EX-99.3
- 99.4 EX-99.4
- 99.5 EX-99.5
- 99.6 EX-99.6
- 99.7 EX-99.7
- 99.8 EX-99.8
- 99.9 EX-99.9
- Download Excel data file
- View Excel data file
Associated filings
- 15 Jan 21 EFFECT Notice of effectiveness
- 14 Jan 21 424B3 Prospectus supplement
-
12 Jan 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 22 Dec 20 S-4 Registration of securities issued in business combination transactions
VIRX similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 10, 2020, except for Note 14 for the retroactive effect of the 1-for-10 reverse stock split, as to which the date is December 22, 2020, included in the Proxy Statement of Sunesis Pharmaceuticals, Inc. that is made a part of the Amendment No. 1 to the Registration Statement (Form S-4 No. 333-251567) and related Prospectus of Sunesis Pharmaceuticals, Inc. for the registration of shares of its common stock.
/s/Ernst & Young LLP
Salt Lake City, Utah
January 12, 2021